ImmuneOncia Therapeutics, Inc. (KOSDAQ:424870)

ImmuneOncia Therapeutics Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	83,070	8,238	8,226	20,957	26,730	36,320
Short-Term Investments	10,100	15,200	3,100	5,000	-	6,000
Cash & Short-Term Investments	93,170	23,438	11,326	25,957	26,730	42,320
Cash Growth	141.40%	106.93%	-56.36%	-2.89%	-36.84%	104.10%
Accounts Receivable	-	-	421.83	11	633.65	-
Other Receivables	134.62	128.37	7,709	172.13	202.16	41.53
Receivables	134.62	128.37	8,131	183.13	835.81	41.53
Prepaid Expenses	5,520	2,475	297.34	376.95	520.18	232.62
Other Current Assets	281.2	465.54	107.93	118.97	884.02	72.89
Total Current Assets	99,106	26,506	19,863	26,636	28,970	42,667
Property, Plant & Equipment	534.54	649	494.54	892.1	547.33	997.96
Other Intangible Assets	4,238	4,503	4,908	5,429	5,987	6,503
Other Long-Term Assets	1,265	1,487	930.02	838.32	188.36	932.89
Total Assets	105,143	33,146	26,195	33,795	35,693	51,101

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accrued Expenses	155.61	138.88	137.63	103.34	154.4	128.24
Current Portion of Leases	31.52	54.98	51.05	50.11	98.69	216.39
Current Unearned Revenue	1,950	1,950	1,950	1,950	1,950	6,902
Other Current Liabilities	2,363	2,115	4,354	1,268	1,646	1,578
Total Current Liabilities	4,500	4,259	6,493	3,372	3,850	8,824
Long-Term Leases	10.12	14.55	44.01	86.83	24.27	98.24
Pension & Post-Retirement Benefits	215.04	139.2	15.06	14.27	-	184.09
Other Long-Term Liabilities	136.94	317.13	219.18	236.63	84,226	101,526
Total Liabilities	4,862	4,730	6,771	3,710	88,100	110,633

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	45,636	37,083	36,365	26,896	26,141	25,503
Additional Paid-In Capital	188,852	115,752	79,021	35,292	28,046	22,148
Retained Earnings	-147,606	-138,091	-110,721	-105,016	-113,921	-110,518
Comprehensive Income & Other	13,399	13,672	14,759	8,637	7,326	3,336
Total Common Equity	100,281	28,415	19,424	-34,192	-52,407	-59,532
Shareholders' Equity	100,281	28,415	19,424	30,086	-52,407	-59,532
Total Liabilities & Equity	105,143	33,146	26,195	33,795	35,693	51,101

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	41.65	69.53	95.06	136.94	122.97	314.63
Net Cash (Debt)	93,128	23,368	11,231	25,820	26,607	42,005
Net Cash Growth	141.73%	108.06%	-56.50%	-2.96%	-36.66%	103.58%
Net Cash Per Share	1225.24	332.76	199.46	492.28	510.53	904.13
Filing Date Shares Outstanding	81.29	74.17	56.31	52.45	52.12	46.46
Total Common Shares Outstanding	81.29	74.17	56.31	52.45	52.12	46.46
Working Capital	94,606	22,247	13,370	23,264	25,120	33,842
Book Value Per Share	1233.61	383.14	344.97	-651.90	-1005.59	-1281.39
Tangible Book Value	96,043	23,913	14,516	-39,621	-58,394	-66,035
Tangible Book Value Per Share	1181.48	322.42	257.81	-755.41	-1120.48	-1421.36
Machinery	1,823	1,797	1,514	1,443	1,173	1,148

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 4, 2026

Data Sources Report a data error